Portal Instruments, a leader in innovative drug delivery solutions, will showcase its new device, PRIME Nexus, at the Pre-Filled Syringes and Injectable Drug Devices conference in Boston, April 28-30.
BOSTON, MA – April 8, 2025 – Portal Instruments, a leader in innovative drug delivery solutions, will showcase its new device, PRIME Nexus, at the Pre-Filled Syringes and Injectable Drug Devices conference in Boston, April 28-30.
PRIME Nexus is a reusable electro-mechanical autoinjector, leveraging Portal’s PRIME needle-free platform. Compatible with 1.0 mL and 2.25 mL pre-filled syringes, Nexus offers a sustainable solution for a wide range of injectable medications and is currently available for feasibility studies.
Attendees are invited to meet with CCO Steven Kaufman for personalized demonstrations and to discuss the device's capabilities. “We’re thrilled to present PRIME Nexus alongside Gerresheimer at the PFS conference,” stated Kaufman. “The surge in injectable therapies, exemplified by GLP-1 drugs, necessitates a shift towards reusable solutions to mitigate the significant waste generated by single-use devices. PRIME Nexus represents a forward-thinking approach to injector technology.”
For companies traveling to Boston, the Portal team extends an invitation to visit their Cambridge office for a closer look at their technology.
January 2025 – Portal Instruments, a leader in innovative drug delivery technology, recently announced the launch of PRIME Nexus, a cutting-edge reusable electronic injector designed to enhance the administration of injectable medications while helping partners meet their sustainability goals.
December 2019 - Jay Sparks, host of Finding Unique Value podcast, chats with Dr. Anquetil about how he has leveraged his unique science and business background to create value and solve an unmet need with potential to help millions of people.
September 2021 - Patrick Anquetil sat down with ASAP Biopharma ahead of his keynote "Alliance Managers Are Bringing Digital Health Innovation" which is slated for 10:20 a.m. EDT on September 28th. The keynote will be followed by a Q&A session.
Please fill out the details below and we will get back to you shortly.